BioNTech’s (BNTX) “Buy” Rating Reaffirmed at Truist Financial

Truist Financial reissued their buy rating on shares of BioNTech (NASDAQ:BNTX) in a research note released on Tuesday morning,Benzinga reports. The firm currently has a $155.00 target price on the stock, up from their previous target price of $151.00.

Several other brokerages have also recently issued reports on BNTX. Canaccord Genuity Group restated a “buy” rating and issued a $171.44 target price on shares of BioNTech in a report on Tuesday, March 11th. Morgan Stanley dropped their target price on shares of BioNTech from $140.00 to $132.00 and set an “overweight” rating on the stock in a report on Tuesday, May 6th. HC Wainwright restated a “buy” rating and issued a $134.00 target price on shares of BioNTech in a report on Thursday, May 22nd. BMO Capital Markets lifted their price target on shares of BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 11th. Finally, Wall Street Zen downgraded shares of BioNTech from a “hold” rating to a “sell” rating in a research report on Friday, May 30th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, BioNTech currently has an average rating of “Moderate Buy” and an average price target of $139.14.

BioNTech Trading Up 2.2%

NASDAQ:BNTX opened at $115.64 on Tuesday. BioNTech has a 52 week low of $76.53 and a 52 week high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The company’s 50 day moving average price is $98.19 and its 200-day moving average price is $108.26. The stock has a market cap of $27.80 billion, a price-to-earnings ratio of -55.07 and a beta of 1.35.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.24 billion. During the same quarter last year, the company posted $1.90 earnings per share. The firm’s quarterly revenue was down 19.5% on a year-over-year basis. On average, equities research analysts forecast that BioNTech will post -3.88 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Banque Cantonale Vaudoise bought a new position in BioNTech in the 1st quarter worth $36,000. Jones Financial Companies Lllp boosted its holdings in BioNTech by 110.3% in the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock worth $53,000 after buying an additional 246 shares during the period. Banque Transatlantique SA bought a new position in BioNTech in the 1st quarter worth $80,000. Quintet Private Bank Europe S.A. boosted its holdings in BioNTech by 823.5% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock worth $88,000 after buying an additional 700 shares during the period. Finally, Allianz SE bought a new position in BioNTech in the 4th quarter worth $90,000. Institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.